

Inc., North Andover, MA has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NIIP-SMART intends to file additional written notification disclosing all changes in membership.

On May 1, 1996, NIIP-SMART filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on April 29, 1997 (62 FR 23268).

The last notification was filed with the Department on November 19, 1997. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on February 5, 1998 (63 FR 5970).

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*  
[FR Doc. 99-26179 Filed 10-6-99; 8:45 am]

BILLING CODE 4410-11-M

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Salutation Consortium, Inc.

Notice is hereby given that, on May 6, 1999, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Salutation Consortium, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership status. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Okamura Corporation, Yokohama Kanagawa, JAPAN has been dropped as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Salutation Consortium, Inc. intends to file additional written notification disclosing all changes in membership.

On March 30, 1995, Salutation Consortium, Inc. filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on June 27, 1995 (60 FR 33233).

The last notification was filed with the Department on February 8, 1999. A notice has not yet been published in the **Federal Register**.

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*  
[FR Doc. 99-26183 Filed 10-6-99 8:45 am]

BILLING CODE 4410-11-M

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Seagate Technology, Inc., Advanced Research Corporation, Imation Corp., and Peregrine Recording Technology, Inc.

Notice is hereby given that, on January 7, 1999, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Seagate Technology, Inc., Advanced Research Corporation, Imation Corp., and Peregrine Recording Technology, Inc., have filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing: (1) The identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to section 6(b) of the Act, the identities of the parties are Seagate Technology, Inc., Santa Maria, CA; Advanced Research Corporation, Minneapolis, MN; Imation Corp., Oakdale, MN; and Peregrine Recording Technology, Inc., St. Paul, MN. The nature and objectives of the venture are to develop technologies for a small, reliable, low cost, high-bandwidth, high-capacity, fast access tape recorder and cartridge media.

The planned joint activity was begun under a joint research and development venture entered into on September 15, 1995 between Minnesota Mining and Manufacturing Company (3M), Seagate Tape Technology, Inc., and Advanced Research Corporation (60 FR 62260).

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*  
[FR Doc. 99-26182 Filed 10-6-99; 8:45 am]

BILLING CODE 4410-11-M

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—the SNP Consortium Ltd. ("TSC")

Notice is hereby given that, on April 21, 1999, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), The SNP Consortium Ltd. ("TSC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing: (1) The identities of the parties; and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are Bayer Corporation, Tarrytown, NY; Bristol-Myers Squibb Company, Princeton, NJ; Glaxo Wellcome Inc., Research Triangle Park, NJ; Hoechst Marion Roussel Inc., Bridgewater, NJ; Hoffmann-La Roche Inc., Nutley, NJ; Monsanto Company, St. Louis, MO; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Pfizer Inc., New York, NY; SmithKline Beecham Corporation, Philadelphia, PA; The Wellcome Trust Limited, as trustee of the Wellcome Trust, London, England; and Zeneca Inc., Wilmington, DE. The nature and objectives of the venture are to carry on scientific research in the public interest, including research intended to advance the field of human medicine by creating a single nucleotide polymorphism ("SNP") map on the human genome, that will then be made freely available to the public on a nondiscriminatory basis. The joint venture will enable TSC to create a high-density, high-quality SNP map with shared financial risk and without the duplication of effort that would result from the work of individual members. As the SNP map is being constructed, it will be placed in the public domain for use by the worldwide medical research community in identifying specific genes involved in various diseases, thereby facilitating downstream research and development of therapeutic, diagnostic and pharmaceutical products.

**Constance K. Robinson,**

*Director of Operations, Antitrust Division.*  
[FR Doc. 99-26184 Filed 10-6-99; 8:45 am]

BILLING CODE 4410-11-M